oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 28 )

2018 ( 636 )

2017 ( 680 )

2016 ( 762 )

Custom range...

Search Results: 1 - 10 of 16422 matches for " tumor necrosis factor α "
All listed articles are free for downloading (OA Articles)
Page 1 /16422
Display every page Item
Multifaceted role of TNF-α during the pathogenesis of rheumatoid arthritis  [PDF]
Ramanjaneya V. R. Mula, Rangaiah Shashidharamurthy
Advances in Bioscience and Biotechnology (ABB) , 2013, DOI: 10.4236/abb.2013.410123
Abstract:

Tumor necrosis factor alpha (TNF-α) a cytokine has been shown to be the key player during the pathogenesis of several autoimmune inflammatory disorders (presumably sterile inflammation) including rheumatoid arthritis (RA). Several studies have shown that TNF-α is mainly involved in the proinflammatory responses. However recent studies have reported multifunctional role of TNF-α during the development of RA. Therefore, in this article we have highlighted the distinct functions of TNF-α during pathogenesis of RA.  

Efficacy of Infliximab Therapy for a Patient with Superficial Thrombophlebitis and Rheumatoid Arthritis  [PDF]
Masahiro Tada, Kazuyoshi Fukai, Tadashi Okano, Yuko Sugioka, Shigeyuki Wakitani, Hiroaki Nakamura, Tatsuya Koike
International Journal of Clinical Medicine (IJCM) , 2011, DOI: 10.4236/ijcm.2011.24077
Abstract: Superficial thrombophlebitis is known as a frequent complication of Behçet’s disease. Infliximab may promote healing of superficial thrombophlebitis in patients with Behçet’s disease. However, thrombophlebitis as a complication of rheumatoid arthritis (RA) is rare and treatments have not been reported. We describe the case of a 47-year-old man with RA with complications of superficial thrombophlebitis who was treated using methotrexate and infliximab. Erythema nodosum and cord-like induration with pain in the extremities completely disappeared following a single infusion of infliximab and oral acetylsalicylic acid was not needed. This case suggests that infliximab might offer effective treatment for patients showing superficial thrombophlebitis with RA.
Resolution of Chronic Subdural Hematoma after Treatment with Tumor Necrosis Factor Alpha Inhibitor  [PDF]
Donald Ross
Neuroscience & Medicine (NM) , 2011, DOI: 10.4236/nm.2011.24045
Abstract: Background and Importance: Chronic subdural hematomas (cSDH) are a common problem for which solutions remain imperfect. Surgery is effective, but not without risk. Recent data have suggested a role for inflammation in the genesis of cSDH and several reports have documented some benefit to steroid treatment. In this report, a possible role for tumor necrosis factor alpha blockade in the resolution of a multiply recurrent cSDH is described. Clinical Presentation: An 86-year-old man with rheumatoid arthritis treated with infliximab presented with a large, symptomatic, multiloculated cSDH. Infliximab was withheld and craniotomy for evacuation was uncomplicated, but recurrent symptoms were noted and a recurrence was operated upon again several weeks later. Follow up CT showed a second recurrence. The patient requested to go back on his infliximab due to painful arthralgias. After a single dose of 10 mg/kg, follow up CT showed that the cSDH resolved and did not recur. Conclusion: Anti-TNF-alpha treatment with infliximab may have played a role in the resolution of this patient’s cSDH. Further investigation of this possible effect seems warranted.
Pro-inflammatory cytokine; tumor-necrosis factor-alpha (TNF-α) inhibits astrocytic support of neuronal survival and neurites outgrowth  [PDF]
Ebtesam M. Abd-El-Basse
Advances in Bioscience and Biotechnology (ABB) , 2013, DOI: 10.4236/abb.2013.48A2010
Abstract:

Reactive astrogliosis has been implicated in the failure of axonal regeneration in adult mammalian Central Nervous System (CNS). It is our hypothesis that inflammatory cytokines act upon astrocytes to alter their biochemical and physical properties, which may in turn be responsible for the failure of neuronal regeneration. We have therefore examined the effect of tumor-necrosis factor-alpha (TNF-α) on the ability of astrocytes to support the survival of the cortical neurons and the growth of the neurites. Mouse astrocytes and cortical neuronal cultures were prepared. It was observed that when neurons were cultured in absence of astrocytes only a few of them grew and survived only for 5-6 days. These neurons had small cell bodies and few, short neurites. However, when the same numbers of neurons were cultured on the top of astrocytes, more neurons grew and survived up to 16-18 days. They had bigger cell bodies and many long branched neurites that formed anestamosing networks. The neurons then coalesced and the neurites formed thick bundles. When the same numbers of neurons were grown on the top of astrocytes pre-treated with TNF-α, few neurons survived up to 13 days. The neurites of the survived neurons were shorter than neurites of neurons grown on normal astrocytes and did not form bundles. In addition, TNF-α stimulated the expression of glial fibrillary acidic protein (GFAP) by astrocytes. These results support that the pro-inflammatory cytokine, TNF-α modulates the gliosis and that the astrocytic cell supports neuronal survival and neurite outgrowth.

Tuberculosis pleural asociada con adalimumab, en un paciente con artritis reumatoide
Hidalgo,Patricia; Echeverri,Jorge; Gutiérrez,Juan Martín;
Infectio , 2010,
Abstract: tuberculosis (tb) represents one of the endemic infectious diseases in our population. the incidence of reactivate tb cases has grown notoriously with the onset of new therapeutic options for controlling rheumatoid arthritis (ra), such as tumor necrosis factor (tnf) inhibitors. the case of a 42 year old woman is highlighted. her condition is characterized by shortness of breath, chest pain, cough, pleural effusion, linfocitic exudate pleural fluid, ada 55 u-l and granuloma in pleural biopsy.a review of relevant literature and recommendations are presented.
Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habituales
Labarca S,Cristián; Massardo V,Loreto; García M,Paula I; Jacobelli G,Sergio;
Revista médica de Chile , 2003, DOI: 10.4067/S0034-98872003001000009
Abstract: tumor necrosis factor antagonists are useful in the treatment of several chronic inflammatory immune mediated diseases. aim: to assess the effects of infliximab in 21 patients with inflammatory arthropaties, refractary to conventional treatment. patients and methods: eleven patients with rheumatoid arthritis, seven with psoriatic arthritis and three with spondyloarthritis were treated. the mean duration of the diseases was 10 years. infliximab was administered intravenously in a dose of 3 mg/kg body weight. a median of 6 doses in 8 months was administered. effectiveness was assessed in 19 patients that received three or more doses. results: infliximab was effective in 16 patients (10 with rheumatoid arthritis, four with psoriasis and two with spondyloarthritis) and ineffective in three. in responsive patients, a reduction in the number of inflammed joints and morning stiffness and an improvement in functional capacity was observed. fifteen of the 16 patients perceived an improvement in their health status. this answer was concordant with concomitant medical evaluation in 15. patients that maintained the treatment felt very well, well or regular, whereas five of six patients that discontinued the treatment felt ill. thirteen patients had adverse effects. treatment was discontinued in two patients due to drug induced lupus, allergy in 2, hypertension in one, high costs in three and lack of response in three. conclusions: infliximab reduced arthritic activity in 16 of 19 patients with severe treatment refractary arthritis (rev méd chile 2003; 131: 1157-64).
Nuevas armas inmunológicas para la medicina del siglo XXI: Terapia biológica basada en el uso de anticuerpos monoclonales de última generación
Aguillón G,Juan C; Contreras L,Juan; Dotte G,Andrés; Cruzat C,Andrea; Catalán M,Diego; Salazar A,Lorena; Molina S,María Carmen; Guerrero P,Julia; López N,Mercedes; Soto S,Lilian; Salazar-Onfray,Flavio; Cuchacovich T,Miguel;
Revista médica de Chile , 2003, DOI: 10.4067/S0034-98872003001200013
Abstract: the fusion of a murine b cell and a myeloma cell generates a hybridoma that produces monoclonal antibody (mab). these murine mab induce the hama (human anti-mouse antibodies) response. murine mab have been modified by genetic engineering, producing molecules with a higher proportion of human protein. at present, chimeric, humanized and fully human mab are available. mab block interactions between target molecules and their ligands or trigger the lyses of mab-coated tumor cells. numerous mab have been developed using the recombinant dna technology and several are available in the market. trastuzumab, against her2/neu, is useful in breast cancer; rituximab, against cd20 in b lymphocytes is useful in lymphoma; alemtuzumab, against cd52 is used in lymphoma and leukemia; daclizumab and basiliximab block the il-2 receptor interaction and reduce acute rejection in kidney transplantion; abciximab, an antagonist of gpiib/iiia platelet receptor, is used in patients undergoing acute coronary syndromes. in autoimmunity diseases, blocking tumor necrosis factor by infliximab and adalimumab has demonstrated excellent results. thus, infliximab is useful in the treatment of rheumatoid arthritis (ra), crohn's disease and ulcerative colitis while adalimumab is the first fully human mab available for ra. infliximab and adalimumab reduce signs and symptoms in ra and they also interfere with progression of joint damage. finally, the direct benefits of antagonist treatment can occur at the expense of a major adverse effect in some other biological function (rev méd chile 2003; 131: 1445-53).
Chronic stress sensitizes rats to pancreatitis induced by cerulein: Role of TNF-α
Marcelo G Binker, Andres A Binker-Cosen, Daniel Richards, Herbert Y Gaisano, Rodica H de Cosen, Laura I Cosen-Binker
World Journal of Gastroenterology , 2010,
Abstract: AIM: To investigate chronic stress as a susceptibility factor for developing pancreatitis, as well as tumor necrosis factor-α (TNF-α) as a putative sensitizer.METHODS: Rat pancreatic acini were used to analyze the influence of TNF-α on submaximal (50 pmol/L) cholecystokinin (CCK) stimulation. Chronic restraint (4 h every day for 21 d) was used to evaluate the effects of submaximal (0.2 μg/kg per hour) cerulein stimulation on chronically stressed rats.RESULTS: In vitro exposure of pancreatic acini to TNF-α disorganized the actin cytoskeleton. This was further increased by TNF-α/CCK treatment, which additionally reduced amylase secretion, and increased trypsin and nuclear factor-κB activities in a protein-kinase-C δ and ε-dependent manner. TNF-α/CCK also enhanced caspases’ activity and lactate dehydrogenase release, induced ATP loss, and augmented the ADP/ATP ratio. In vivo, rats under chronic restraint exhibited elevated serum and pancreatic TNF-α levels. Serum, pancreatic, and lung inflammatory parameters, as well as caspases’activity in pancreatic and lung tissue, were substantially enhanced in stressed/cerulein-treated rats, which also experienced tissues’ ATP loss and greater ADP/ATP ratios. Histological examination revealed that stressed/cerulein-treated animals developed abundant pancreatic and lung edema, hemorrhage and leukocyte infiltrate, and pancreatic necrosis. Pancreatitis severity was greatly decreased by treating animals with an anti-TNF-α-antibody, which diminished all inflammatory parameters, histopathological scores, and apoptotic/necrotic markers in stressed/cerulein-treated rats.CONCLUSION: In rats, chronic stress increases susceptibility for developing pancreatitis, which involves TNF-α sensitization of pancreatic acinar cells to undergo injury by physiological cerulein stimulation.
Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habituales Effectiveness of infliximab in patients with inflammatory arthritis refractory to conventional treatment
Cristián Labarca S,Loreto Massardo V,Paula I García M,Sergio Jacobelli G
Revista médica de Chile , 2003,
Abstract: Tumor necrosis factor antagonists are useful in the treatment of several chronic inflammatory immune mediated diseases. Aim: To assess the effects of infliximab in 21 patients with inflammatory arthropaties, refractary to conventional treatment. Patients and methods: Eleven patients with rheumatoid arthritis, seven with psoriatic arthritis and three with spondyloarthritis were treated. The mean duration of the diseases was 10 years. Infliximab was administered intravenously in a dose of 3 mg/kg body weight. A median of 6 doses in 8 months was administered. Effectiveness was assessed in 19 patients that received three or more doses. Results: Infliximab was effective in 16 patients (10 with rheumatoid arthritis, four with psoriasis and two with spondyloarthritis) and ineffective in three. In responsive patients, a reduction in the number of inflammed joints and morning stiffness and an improvement in functional capacity was observed. Fifteen of the 16 patients perceived an improvement in their health status. This answer was concordant with concomitant medical evaluation in 15. Patients that maintained the treatment felt very well, well or regular, whereas five of six patients that discontinued the treatment felt ill. Thirteen patients had adverse effects. Treatment was discontinued in two patients due to drug induced lupus, allergy in 2, hypertension in one, high costs in three and lack of response in three. Conclusions: Infliximab reduced arthritic activity in 16 of 19 patients with severe treatment refractary arthritis (Rev Méd Chile 2003; 131: 1157-64).
Nuevas armas inmunológicas para la medicina del siglo XXI: Terapia biológica basada en el uso de anticuerpos monoclonales de última generación Biological therapy based on the use of last generation monoclonal antibodies
Juan C Aguillón G,Juan Contreras L,Andrés Dotte G,Andrea Cruzat C
Revista médica de Chile , 2003,
Abstract: The fusion of a murine B cell and a myeloma cell generates a hybridoma that produces monoclonal antibody (mAb). These murine mAb induce the HAMA (human anti-mouse antibodies) response. Murine mAb have been modified by genetic engineering, producing molecules with a higher proportion of human protein. At present, chimeric, humanized and fully human mAb are available. mAb block interactions between target molecules and their ligands or trigger the lyses of mAb-coated tumor cells. Numerous mAb have been developed using the recombinant DNA technology and several are available in the market. Trastuzumab, against HER2/neu, is useful in breast cancer; rituximab, against CD20 in B lymphocytes is useful in lymphoma; alemtuzumab, against CD52 is used in lymphoma and leukemia; daclizumab and basiliximab block the IL-2 receptor interaction and reduce acute rejection in kidney transplantion; abciximab, an antagonist of GPIIb/IIIa platelet receptor, is used in patients undergoing acute coronary syndromes. In autoimmunity diseases, blocking tumor necrosis factor by infliximab and adalimumab has demonstrated excellent results. Thus, infliximab is useful in the treatment of rheumatoid arthritis (RA), Crohn's disease and ulcerative colitis while adalimumab is the first fully human mAb available for RA. Infliximab and adalimumab reduce signs and symptoms in RA and they also interfere with progression of joint damage. Finally, the direct benefits of antagonist treatment can occur at the expense of a major adverse effect in some other biological function (Rev Méd Chile 2003; 131: 1445-53).
Page 1 /16422
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.